Paratek Pharmaceuticals, Inc.
PRTK
PRTK was delisted on the 20th of September, 2023.
93 hedge funds and large institutions have $92.2M invested in Paratek Pharmaceuticals, Inc. in 2019 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 38 increasing their positions, 22 reducing their positions, and 12 closing their positions.
73% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 22
17% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 12
2% more funds holding
Funds holding: 91 → 93 (+2)
6% less capital invested
Capital invested by funds: $98.5M → $92.2M (-$6.29M)
15% less call options, than puts
Call options by funds: $350K | Put options by funds: $414K
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$4.3M |
| 2 |
AC
Armistice Capital
New York
|
+$2.41M |
| 3 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
+$1.85M |
| 4 |
PM
Prosight Management
Dallas,
Texas
|
+$1.56M |
| 5 |
D.E. Shaw & Co
New York
|
+$840K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Baupost Group
Boston,
Massachusetts
|
-$10.3M |
| 2 |
RAM
Roumell Asset Management
Chevy Chase,
Maryland
|
-$1.43M |
| 3 |
RA
Royce & Associates
New York
|
-$1.27M |
| 4 |
BlackRock
New York
|
-$1.12M |
| 5 |
APCM
Arbiter Partners Capital Management
New York
|
-$896K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SFSIG
101
San Francisco Sentry Investment Group
San Francisco,
California
| – | -$1K | -200 | Closed |
|
102
Daiwa Securities Group
Tokyo,
Japan
| – | -$1K | -173 | Closed |
|
103
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | +$243 | +70 | +31% |
|
PRTK Hedge Fund Activity: Q4 2019 in Review
93 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Paratek Pharmaceuticals, Inc. (PRTK) for Q4 2019, worth a combined $92.2M — down 6.4% from $98.5M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new PRTK positions and 12 closed out — a net gain of 2 holders — while 38 added to existing stakes and 22 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $4.3M. The largest seller was Baupost Group, exiting entirely with an estimated $10.3M sold.
- 93 institutional investors held Paratek Pharmaceuticals, Inc. (PRTK) as of Q4 2019, up from 91 in Q3 2019.
- Funds reported $92.2M of Paratek Pharmaceuticals, Inc. stock for Q4 2019, down 6.4% quarter-over-quarter.
- 14 funds opened new Paratek Pharmaceuticals, Inc. positions in Q4 2019 and 12 closed out, a net change of +2 holders.
- The largest Paratek Pharmaceuticals, Inc. buyer in Q4 2019 was JP Morgan Chase, an estimated $4.3M added.
- The largest Paratek Pharmaceuticals, Inc. seller in Q4 2019 was Baupost Group, an estimated $10.3M sold.
Based on aggregated 13F filings for Q4 2019.